Oscar Health (OSCR) presents a high-risk, high-reward opportunity based on its aggressive growth targets in the health insurance market. The company aims for 20% annual revenue growth, which could lead to the stock doubling in value by 2027. However, this potential is heavily dependent on the Affordable Care Act (ACA), which accounts for nearly all of its revenue. A significant risk exists as ACA subsidies could end in 2026, creating major headwinds for the business. Due to this high political uncertainty, investors may consider waiting for a clearer outlook before investing in OSCR.

Oscar Health (OSCR)

• Company Profile: Oscar Health is a technology-driven health insurance company focused on individuals and small businesses, capitalizing on the growth of the gig economy and freelancing.
• Current Financials (at time of recording):
  • Share Price: $19
  • Market Cap: $5.8 billion
  • Enterprise Value: $5.6 billion
  • Revenue (Last 12 Months): $10 billion
  • Net Income (Last 12 Months): $123 million
  • Adjusted EBITDA (Last 12 Months): $508 million
• Valuation Multiples:
  • The stock is trading at 47 times earnings and 11 times EBITDA.
• Growth & Performance:
  • Membership has grown from 400,000 in December 2020 to over 2 million.
  • Annual revenues have increased by over 2,000% during the same period.
  • The company recently posted its first-ever GAAP profit.
• Bull Case (The Upside):
  • The CEO has a confident outlook, targeting at least 20% annual revenue growth for the next three years and a 5% operating margin.
  • This projects to $15.9 billion in revenue and $800 million in operating income by 2027.
  • Based on these targets, the analyst projects a potential market cap of $11 billion, which would be roughly a double from its current valuation.
• Bear Case (The Risks):
  • The company has a very high concentration risk, with 97% of its revenue coming from plans sold under the Affordable Care Act (ACA), also known as Obamacare.
  • The ACA is facing political pressure, and there is a risk that subsidies could end in 2026.
  • The Washington Post estimates 17 million Americans could lose healthcare coverage if subsidies end, many of whom are Oscar's customers. This could create "significant pressures" for the company next year.
• Counter-Arguments & Other Factors:
  • Oscar's management claims its growth targets already account for the potential end of ACA subsidies.
  • A separate government initiative, the Individual Coverage HRA (ICRA), could provide a new growth avenue by allowing individuals to use employer contributions to select their own insurance.

Takeaways

• High-Risk, High-Reward: Oscar Health presents a clear bull case based on strong execution and growth, but it is paired with significant political and regulatory risk.
• The Bullish Bet: An investment in OSCR is a bet that management can achieve its ambitious growth targets (20% annual revenue growth) despite the political headwinds. If successful, the stock has a clear path to double in value by 2027.
• The Bearish Concern: The heavy dependence on the ACA is the single biggest risk. Investors must be comfortable with the high level of uncertainty surrounding the future of healthcare subsidies in the U.S.
• Analyst's Conclusion: The podcast host views Oscar as a "highly promising insurance business" but notes there are many "moving parts" and high uncertainty for the coming year. The host suggests that while the company is worth watching, there "may be better chances to buy the stock" in the future, possibly after the political landscape becomes clearer.